

# Jorge Carrillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7286659/publications.pdf>

Version: 2024-02-01

77  
papers

2,890  
citations

172457

29  
h-index

197818

49  
g-index

82  
all docs

82  
docs citations

82  
times ranked

5578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. <i>Cell Reports Medicine</i> , 2022, 3, 100523.	6.5	18
2	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	39
3	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. <i>Frontiers in Immunology</i> , 2022, 13, 860215.	4.8	6
4	Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studies. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1721-1725.	3.0	51
5	Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. <i>Clinical Microbiology and Infection</i> , 2021, 27, 651-652.	6.0	5
6	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 187-191.	2.1	86
7	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. <i>Scientific Reports</i> , 2021, 11, 2608.	3.3	86
8	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. <i>Frontiers in Pharmacology</i> , 2021, 12, 646676.	3.5	40
9	Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	95
10	Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. <i>Med</i> , 2021, 2, 313-320.e4.	4.4	77
11	High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202001009.	2.8	8
12	Monitoring Natural SARS-CoV-2 Infection in Lions ( <i>Panthera leo</i> ) at the Barcelona Zoo: Viral Dynamics and Host Responses. <i>Viruses</i> , 2021, 13, 1683.	3.3	51
13	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <i>Membranes</i> , 2021, 11, 64.	3.0	0
14	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. <i>Emerging Microbes and Infections</i> , 2021, 10, 797-809.	6.5	42
15	SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2676-2678.	10.5	36
16	First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain. <i>Viruses</i> , 2021, 13, 2526.	3.3	20
17	Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery. <i>Frontiers in Immunology</i> , 2020, 11, 582330.	4.8	4
18	Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. <i>PLoS Pathogens</i> , 2020, 16, e1008678.	4.7	25

#	ARTICLE	IF	CITATIONS
19	Gut T cell-independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells. <i>Science Immunology</i> , 2020, 5, .	11.9	40
20	Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24790-24793.	7.1	154
21	Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations. <i>Polymers</i> , 2020, 12, 2392.	4.5	0
22	Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 978-990.	1.2	87
23	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	7.1	70
24	A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults. <i>Frontiers in Immunology</i> , 2020, 11, 614319.	4.8	0
25	Production of HIV-1-based virus-like particles for vaccination: achievements and limits. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 7367-7384.	3.6	30
26	B-Lymphocyte Phenotype Determines T-Lymphocyte Subset Differentiation in Autoimmune Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 1732.	4.8	4
27	Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection. <i>PLoS ONE</i> , 2019, 14, e0218000.	2.5	11
28	Evolution of the gut microbiome following acute HIV-1 infection. <i>Microbiome</i> , 2019, 7, 73.	11.1	69
29	New emerging targets in cancer immunotherapy: the role of neoantigens. <i>ESMO Open</i> , 2019, 4, e000684.	4.5	20
30	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. <i>Mucosal Immunology</i> , 2019, 12, 232-246.	6.0	56
31	Memory B cell dysregulation in HIV-1-infected individuals. <i>Aids</i> , 2018, 32, 149-160.	2.2	11
32	Secreted IgD Amplifies Humoral T Helper 2 Cell Responses by Binding Basophils via Galectin-9 and CD44. <i>Immunity</i> , 2018, 49, 709-724.e8.	14.3	60
33	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2429.	4.8	15
34	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7854-E7862.	7.1	28
35	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. <i>Scientific Reports</i> , 2017, 7, 40800.	3.3	12
36	A Cytokine Pattern That Differentiates Preseroconversion From Postseroconversion Phases of Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 459-466.	2.1	19

#	ARTICLE	IF	CITATIONS
37	Interferon- $\gamma$ -Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2017, 65, 1670-1675.	5.8	22
38	IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings. <i>Scientific Reports</i> , 2017, 7, 8104.	3.3	26
39	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. <i>Frontiers in Immunology</i> , 2017, 8, 1154.	4.8	30
40	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. <i>PLoS ONE</i> , 2017, 12, e0184433.	2.5	17
41	Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults. <i>Frontiers in Immunology</i> , 2017, 8, 1925.	4.8	23
42	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017, 12, e0184929.	2.5	13
43	Cell anergy induces a Th17 shift in a novel B lymphocyte transgenic NOD mouse model, the 116C $\alpha$ NOD mouse. <i>European Journal of Immunology</i> , 2016, 46, 593-608.	2.9	8
44	The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells. <i>Journal of Experimental Medicine</i> , 2016, 213, 2167-2185.	8.5	69
45	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. <i>Aids</i> , 2016, 30, 2275-2287.	2.2	10
46	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	6.1	328
47	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. <i>Journal of Translational Medicine</i> , 2015, 13, 230.	4.4	33
48	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Na $\ddot{v}$ e Chronically HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0120648.	2.5	5
49	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015, 13, 60.	4.4	84
50	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	3.0	56
51	In Vivo Detection of Peripherin-Specific Autoreactive B Cells during Type 1 Diabetes Pathogenesis. <i>Journal of Immunology</i> , 2014, 192, 3080-3090.	0.8	17
52	Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals. <i>Retrovirology</i> , 2014, 11, 44.	2.0	19
53	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. <i>Journal of Translational Medicine</i> , 2013, 11, 68.	4.4	92
54	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. <i>Journal of Translational Medicine</i> , 2013, 11, 48.	4.4	3

#	ARTICLE	IF	CITATIONS
55	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013, 10, 42.	2.0	38
56	Development and validation of a quantitation assay for fluorescently tagged HIV-1 virus-like particles. <i>Journal of Virological Methods</i> , 2013, 193, 85-95.	2.1	43
57	Assessing main death pathways in T lymphocytes from HIV infected individuals. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 648-658.	1.5	13
58	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.	2.2	15
59	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. <i>Aids</i> , 2012, 26, 2285-2293.	2.2	44
60	Modulation of antibody secreting cells and neutralizing Ab activity in HIV infected individuals undergoing structured treatment interruptions. <i>Retrovirology</i> , 2012, 9, .	2.0	1
61	Low levels of anti-MPER antibodies are detectable in viremic HIV infected. <i>Retrovirology</i> , 2012, 9, .	2.0	0
62	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. <i>PLoS ONE</i> , 2012, 7, e30330.	2.5	13
63	Susceptibility of Human Lymphoid Tissue Cultured <i>ex vivo</i> to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection. <i>PLoS ONE</i> , 2012, 7, e37415.	2.5	2
64	Post traumatic splenic function depending on severity of injury and management. <i>Translational Research</i> , 2011, 158, 118-128.	5.0	7
65	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. <i>Vaccine</i> , 2011, 29, 5250-5259.	3.8	38
66	Immune Correlates of HIV Control. <i>Current Medicinal Chemistry</i> , 2011, 18, 3963-3970.	2.4	4
67	Restricted infection of xenotropic murine leukemia virus-related virus in human lymphoid tissue. <i>Retrovirology</i> , 2011, 8, .	2.0	0
68	Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2010, 160, 207-214.	2.6	75
69	Gene expression profiles for the human pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long-standing diabetes. <i>Clinical and Experimental Immunology</i> , 2009, 159, 23-44.	2.6	105
70	Anti-peripherin B lymphocytes are positively selected during diabetogenesis. <i>Molecular Immunology</i> , 2008, 45, 3152-3162.	2.2	15
71	Natural killer cells are required for accelerated type 1 diabetes driven by interferon- $\gamma$ . <i>Clinical and Experimental Immunology</i> , 2008, 151, 467-475.	2.6	41
72	Phenotype and Functional Characteristics of Islet-Infiltrating B-Cells Suggest the Existence of Immune Regulatory Mechanisms in Islet Milieu. <i>Diabetes</i> , 2007, 56, 940-949.	0.6	20

#	ARTICLE	IF	CITATIONS
73	Peripherin Is a Relevant Neuroendocrine Autoantigen Recognized by Islet-Infiltrating B Lymphocytes. <i>Journal of Immunology</i> , 2007, 178, 6533-6539.	0.8	24
74	Reg (regenerating) gene overexpression in islets from non-obese diabetic mice with accelerated diabetes: role of IFN $\gamma$ . <i>Diabetologia</i> , 2006, 49, 2379-2387.	6.3	38
75	Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. <i>Diabetologia</i> , 2005, 48, 1671-1673.	6.3	11
76	Islet-infiltrating B-Cells in Nonobese Diabetic Mice Predominantly Target Nervous System Elements. <i>Diabetes</i> , 2005, 54, 69-77.	0.6	42
77	IFN $\gamma$ Accelerates Autoimmune Type 1 Diabetes in Nonobese Diabetic Mice and Breaks the Tolerance to $\beta$ Cells in Nondiabetes-Prone Mice. <i>Journal of Immunology</i> , 2004, 173, 6667-6675.	0.8	56